Menthol induces cell-cycle arrest in PC-3 cells by down-regulating G2/M genes, including polo-like kinase 1

Biochemical and Biophysical Research Communications

Volumn 422, Issue 3, 2012, Pages 436-441

  Kim, Su Hwa ^a   Lee, Sanghoon ^b   Piccolo, Stephen R ^c,d   Allen Brady, Kristina ^b   Park, Eun Jung ^a   Chun, Jung Nyeo ^a,e   Kim, Tae Woo ^f   Cho, Nam Hyuk ^a   Kim, In Gyu ^a   So, Insuk ^a,e   Jeon, Ju Hong ^a,e  

^a Seoul National University College of Medicine   (South Korea)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Seoul National University   (South Korea)

^f Korea University College of Medicine   (South Korea)

Author keywords

DNA microarray; Gene set enrichment analysis; Menthol; PLK1; Prostate cancer

Indexed keywords

MENTHOL; POLO LIKE KINASE 1;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; DNA MICROARRAY; DOWN REGULATION; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION PROFILING; M PHASE CELL CYCLE CHECKPOINT; MITOSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL DIVISION; DOWN-REGULATION; G2 PHASE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; MENTHOL; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 84861927255     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.010     Document Type: Article

References (41)

1. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011.
3. Pang B., Zhang H., Wang J., Chen W.Z., Li S.H., Shi Q.G., Liang R.X., Xie B.X., Wu R.Q., Qian X.L., Yu L., Li Q.M., Huang C.F., Zhou J.G. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression. Prostate 2009, 69:1176-1187.
4. Taplin M.E. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat. Clin. Pract. Oncol. 2007, 4:236-244.
5. Harris W.P., Mostaghel E.A., Nelson P.S., Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 2009, 6:76-85.
6. Kumar-Sinha C., Chinnaiyan A.M. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003, 62:19-35.
7. Talantov D., Jatkoe T.A., Bohm M., Zhang Y., Ferguson A.M., Stricker P.D., Kattan M.W., Sutherland R.L., Kench J.G., Wang Y., Henshall S.M. Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. J. Urol. 2010, 184:1521-1528.
8. Varambally S., Yu J., Laxman B., Rhodes D.R., Mehra R., Tomlins S.A., Shah R.B., Chandran U., Monzon F.A., Becich M.J., Wei J.T., Pienta K.J., Ghosh D., Rubin M.A., Chinnaiyan A.M. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8:393-406.
9. Glinsky G.V., Glinskii A.B., Stephenson A.J., Hoffman R.M., Gerald W.L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 2004, 113:913-923.
10. Luo J.H. Gene expression alterations in human prostate cancer. Drugs Today (Barc) 2002, 38:713-719.
11. Yu Y.P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., McDonald C., Thomas R., Dhir R., Finkelstein S., Michalopoulos G., Becich M., Luo J.H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 2004, 22:2790-2799.
12. Stockwin L.H., Han B., Yu S.X., Hollingshead M.G., ElSohly M.A., Gul W., Slade D., Galal A.M., Newton D.L., Bumke M.A. Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int. J. Cancer 2009, 125:1266-1275.
13. Li Y., Mizokami A., Izumi K., Narimoto K., Shima T., Zhang J., Dai J., Keller E.T., Namiki M. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. Prostate 2010, 70:48-60.
14. Patel T., Ishiuji Y., Yosipovitch G. Menthol: a refreshing look at this ancient compound. J. Am. Acad. Dermatol. 2007, 57:873-878.
15. Wondergem R., Ecay T.W., Mahieu F., Owsianik G., Nilius B. HGF/SF and menthol increase human glioblastoma cell calcium and migration. Biochem. Biophys. Res. Commun. 2008, 372:210-215.
16. Kim S.H., Nam J.H., Park E.J., Kim B.J., Kim S.J., So I., Jeon J.H. Menthol regulates TRPM8-independent processes in PC-3 prostate cancer cells. Biochim. Biophys. Acta 2009, 1792:33-38.
17. Copois V., Bibeau F., Bascoul-Mollevi C., Salvetat N., Chalbos P., Bareil C., Candeil L., Fraslon C., Conseiller E., Granci V., Maziere P., Kramar A., Ychou M., Pau B., Martineau P., Molina F., Del Rio M. Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J. Biotechnol. 2007, 127:549-559.
18. Weis S., Llenos I.C., Dulay J.R., Elashoff M., Martinez-Murillo F., Miller C.L. Quality control for microarray analysis of human brain samples: The impact of postmortem factors, RNA characteristics, and histopathology. J. Neurosci. Methods 2007, 165:198-209.
19. Brettschneider J., Collin F., Bolstad B.M., Speed T.P. Quality assessment for short oligonucleotide microarray data. Technometrics 2008, 50:241-264.
20. Guan S.H., Zheng J., Brettschneider J. Microarray data quality assessment for developmental time series. Syst. Biol. Stat. Bioinf. 2007, 79-82.
21. Bolstad B., Collin F., Brettschneider J., Simpson K., Cope L., Irizarry R., Speed T. Quality assessment of Affymetrix GeneChip data. Bioinf. Comput. Biol. Solutions Using R and Bioconductor 2005, 33-47.
22. Bengtsson H., Simpson K., Bullard J., Hansen K. aroma. affymetrix: A Generic Framework in R for Analyzing Small to Very Large Affymetrix Data Sets in Bounded Memory 2008, Department of Statistics, Berkeley.
23. Bolstad B.M., Irizarry R.A., Astrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
24. Dai M., Wang P., Boyd A.D., Kostov G., Athey B., Jones E.G., Bunney W.E., Myers R.M., Speed T.P., Akil H. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005, 33:e175.
25. Reich M., Liefeld T., Gould J., Lerner J., Tamayo P., Mesirov J.P. GenePattern 2.0. Nat. Genet. 2006, 38:500-501.
26. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 2001, 98:5116-5121.
27. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
28. Subramanian A., Kuehn H., Gould J., Tamayo P., Mesirov J.P. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 2007, 23:3251-3253.
29. Kim S.H., Kim S.Y., Park E.J., Kim J., Park H.H., So I., Kim S.J., Jeon J.H. Icilin induces G1 arrest through activating JNK and p38 kinase in a TRPM8-independent manner. Biochem. Biophys. Res. Commun. 2011, 406:30-35.
30. Schiebel E. Gamma-tubulin complexes: binding to the centrosome, regulation and microtubule nucleation. Curr. Opin. Cell Biol. 2000, 12:113-118.
31. Zimmerman W.C., Sillibourne J., Rosa J., Doxsey S.J. Mitosis-specific anchoring of gamma tubulin complexes by pericentrin controls spindle organization and mitotic entry. Mol. Biol. Cell 2004, 15:3642-3657.
32. Haren L., Stearns T., Luders J. Plk1-dependent recruitment of gamma-tubulin complexes to mitotic centrosomes involves multiple PCM components. PLoS One 2009, 4:e5976.
33. Weichert W., Schmidt M., Gekeler V., Denkert C., Stephan C., Jung K., Loening S., Dietel M., Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004, 60:240-245.
34. Reagan-Shaw S., Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J. 2005, 19:611-613.
35. van Vugt M.A., Medema R.H. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005, 24:2844-2859.
36. Barr F.A., Sillje H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 2004, 5:429-440.
37. Lane H.A., Nigg E.A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 1996, 135:1701-1713.
38. Sumara I., Gimenez-Abian J.F., Gerlich D., Hirota T., Kraft C., de la Torre C., Ellenberg J., Peters J.M. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr. Biol. 2004, 14:1712-1722.
39. Haren L., Stearns T., Luders J. Plk1-dependent recruitment of gamma-tubulin complexes to mitotic centrosomes involves multiple PCM components. PLoS One 2009, 4:e5976-5985.
40. Liu X.S., Song B., Elzey B.D., Ratliff T.L., Konieczny S.F., Cheng L., Ahmad N., Liu X. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J. Biol. Chem. 2011, 286:35795-35800.
41. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6:321-330.